Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash & Equivalents: 2023-2024

Historic Cash & Equivalents for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $381.0 million.

  • Monte Rosa Therapeutics' Cash & Equivalents rose 219.83% to $401.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.6 million, marking a year-over-year increase of 219.83%. This contributed to the annual value of $381.0 million for FY2024, which is 61.14% up from last year.
  • According to the latest figures from FY2024, Monte Rosa Therapeutics' Cash & Equivalents is $381.0 million, which was up 61.14% from $236.4 million recorded in FY2023.
  • Monte Rosa Therapeutics' Cash & Equivalents' 5-year high stood at $381.0 million during FY2024, with a 5-year trough of $236.4 million in FY2023.
  • In the last 2 years, Monte Rosa Therapeutics' Cash & Equivalents had a median value of $308.7 million in 2023 and averaged $308.7 million.
  • Data for Monte Rosa Therapeutics' Cash & Equivalents shows a peak YoY spiked of 61.14% (in 2024) over the last 5 years.
  • Over the past 2 years, Monte Rosa Therapeutics' Cash & Equivalents (Yearly) stood at $236.4 million in 2023, then spiked by 61.14% to $381.0 million in 2024.